16 July 2025
16 July 2025
Both AstraZeneca and MSD have secured lucrative licensing deals for two of LaNova’s oncology assets in recent years.
FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.
Cantargia will receive a $33m upfront cash payment and up to an additional $580m in milestone payments.
The acquired product assets from dne pharma include Ventizolve, Levopidon and Metadon Dne.
The developments are directed towards providing improved treatment options for individuals with Alzheimer’s disease.
LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.
The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
